AWHL (Aspira Womens Health) Cyclically Adjusted Revenue per Share: $0.91 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AWHL Aspira Womens Health Inc AWHL
36 GF Score
Price $0.40
GF Value $0.28
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aspira Womens Health Cyclically Adjusted Revenue per Share?

Aspira Womens Health AWHL 36 Cyclically Adjusted Revenue per Share is $0.91 as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aspira Womens Health's adjusted revenue per share for the three months ended in Mar. 2026 was $0.043. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Aspira Womens Health's average Cyclically Adjusted Revenue Growth Rate was -2.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -6.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Aspira Womens Health was -0.50% per year. The lowest was -72.00% per year. And the median was -7.10% per year.

As of today (2026-07-17), Aspira Womens Health's current stock price is $0.3999. Aspira Womens Health's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.91. Aspira Womens Health's Cyclically Adjusted PS Ratio of today is 0.44.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aspira Womens Health was 110.44. The lowest was 0.03. And the median was 7.41.


Aspira Womens Health  (OTCPK:AWHL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aspira Womens Health's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.3999/0.91
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aspira Womens Health was 110.44. The lowest was 0.03. And the median was 7.41.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aspira Womens Health Cyclically Adjusted Revenue per Share Related Terms


Aspira Womens Health Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Aspira Womens Health's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Womens Health Cyclically Adjusted Revenue per Share Chart

Aspira Womens Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 1.09 1.00 0.95 0.91

Aspira Womens Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.92 0.92 0.91 0.91

AWHL vs MDXH, BIOQ, XWEL: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Aspira Womens Health's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Cyclically Adjusted PS Ratio falls into.


AWHL
36GF Score
Aspira Womens Health Inc AWHL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspira Womens Health Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aspira Womens Health's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.043/330.2130*330.2130
=0.043

Current CPI (Mar. 2026) = 330.2130.

Aspira Womens Health Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.204 241.018 0.279
201609 0.179 241.428 0.245
201612 0.231 241.432 0.316
201703 0.201 243.801 0.272
201706 0.240 244.955 0.324
201709 0.183 246.819 0.245
201712 0.199 246.524 0.267
201803 0.162 249.554 0.214
201806 0.153 251.989 0.200
201809 0.154 252.439 0.201
201812 0.183 251.233 0.241
201903 0.160 254.202 0.208
201906 0.225 256.143 0.290
201909 0.198 256.759 0.255
201912 0.202 256.974 0.260
202003 0.188 258.115 0.241
202006 0.114 257.797 0.146
202009 0.180 260.280 0.228
202012 0.208 260.474 0.264
202103 0.207 264.877 0.258
202106 0.241 271.696 0.293
202109 0.223 274.310 0.268
202112 0.248 278.802 0.294
202203 0.253 287.504 0.291
202206 0.276 296.311 0.308
202209 0.265 296.808 0.295
202212 0.259 296.797 0.288
202303 0.279 301.836 0.305
202306 0.297 305.109 0.321
202309 0.227 307.789 0.244
202312 0.204 306.746 0.220
202403 0.182 312.332 0.192
202406 0.194 314.175 0.204
202409 0.147 315.301 0.154
202412 0.140 315.605 0.146
202503 0.106 319.799 0.109
202506 0.068 322.561 0.070
202509 0.063 324.800 0.064
202512 0.052 324.054 0.053
202603 0.043 330.213 0.043

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.91 mean?
Aspira Womens Health (AWHL) has a Cyclically Adjusted Revenue per Share of $0.91 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aspira Womens Health and its competitors.
Is Aspira Womens Health's Cyclically Adjusted Revenue per Share too high?
Aspira Womens Health's current Cyclically Adjusted Revenue per Share is $0.91. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Cyclically Adjusted Revenue per Share compare to MDXH and BIOQ?
Aspira Womens Health's Cyclically Adjusted Revenue per Share of $0.91 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current Cyclically Adjusted Revenue per Share is $0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.40 — trading 42.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.91. Aspira Womens Health's overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Cyclically Adjusted Revenue per Share is $0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.40 is trading 42.8% above its estimated GF Value™ of $0.28. GuruFocus considers Aspira Womens Health to be Significantly Overvalued.

Key valuation signals for AWHL:

  • Cyclically Adjusted Revenue per Share: $0.91
  • GF Value™: $0.28 vs. price of $0.40 (42.8% above fair value)
  • GF Score™: 36/100 with 8 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aspira Womens Health Business Description

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score

Get the complete analysis for AWHL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.28
GF Value